Company Name : Boehringer Ingelheim

Friday, September 20, 2019 6:02PM IST (12:32PM GMT)
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
Ingelheim, Germany & Newton, Mass., United States
  • Boehringer Ingelheim strengthens its retinal disease pipeline portfolio with new co-development and license agreement
  • The partners aim to develop novel therapies with significantly reduced patient burden for eye diseases with limited or only insufficient treatment options using Inflammasome Therapeutics’ intravitreal drug delivery technology
  • Inflammasome Therapeutics is entitled to receive up to $160 million in milestone and gated development payments as well as tiered royalties and other milestones due on commercialization
 

Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelheim’s compounds from its retinal disease pipeline portfolio, Boehringer Ingelheim aims to develop novel therapies for retinal diseases.

 

In 2019 there were an estimated 82 million patients in the seven key countries (U.S., Japan, Germany, U.K., Spain, Italy, France) affected by one of the three major forms of retinal disease: Age related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edema (DME). Globally, the prevalence rates of these and other retinal diseases are expected to increase over the next 10 years primarily due to aging populations and the global diabetes epidemic. Despite therapeutic advances in some disease areas during the past years, the real world results are poor, and there are no or only limited treatment options in many areas, resulting in an overall high unmet need. The collaboration between Boehringer Ingelheim and Inflammasome aims to address this challenge by using Inflammasome’s technology to deliver therapeutics in a biodegradable gel formulation into the eye.

 

“We are delighted to enter into a collaboration with a company of Boehringer Ingelheim’s stature,” said Paul Ashton, Chief Executive Officer of Inflammasome Therapeutics. “We look forward to working with their team to leverage our respective technologies and expertise to develop new therapies for devastating retinal diseases leading to blindness. This collaboration fits our strategy of advancing the company via both collaborations and internal development.”

 

“Boehringer Ingelheim is looking forward to developing Inflammasome’s novel technology for the delivery of our first-in- class retinal disease compounds working jointly with Inflammasome’s highly experienced scientific team,” said Clive R. Wood, PhD, Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. “This will enable us to develop a broad range of novel therapy options for the many patients with retinal diseases waiting urgently for better and new therapy options.”

 

Boehringer Ingelheim takes a holistic approach in the development of novel retinal disease therapies, targeting key mechanisms in the pathogenesis of retinal diseases. The company has built a comprehensive pipeline portfolio of next generation therapy approaches in various stages of development up to Phase 2 in macular degeneration, diabetic retinal diseases and beyond. Inflammasome’s novel delivery technology using a long-acting degradable IVT implant complements this portfolio.

 

Inflammasome is entitled to receive up to $160 million in up-front, research and development support and milestone gated development payments as well as tiered royalties based on future commercial sales of developed products and other milestones due on commercialization.

 

Please click on the link for ´Notes to Editors´and ´References´:

 

http://www.boehringer-ingelheim.com/press-release/collaboration-novel-therapies-retinal-diseases

 

 

Source: BUSINESS WIRE INDIA

Click here for Media Contact Details
CONTACTS :

Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com

Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: + 203-791-6672
linda.ruckel@boehringer-ingelheim.com

Inflammasome Therapeutics
Bev. Jedynak
Bevlyn Consulting
+1 312 943 1123
+1 773 350 5793
blj@bevylnconsulting.com


More News from Boehringer Ingelheim

Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing

30/10/2019 11:20AM

Results were presented from the company’s pan-KRAS program including BI 1701963, which is being investigated alone and in combination with MEK inhibition in an ongoing Phase I clinical study in cancer ...

Interim analysis from EMPRISE real-world study shows empagliflozin decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists

18/11/2019 3:40PM

This analysis on effectiveness also shows empagliflozin was associated with a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors or GLP-1 receptor agonists1 A second ...

Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilised

14/11/2019 11:01AM

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced the initiation of EMPULSE, the sixth Phase III study in the empagliflozin heart failure programme. The study will assess whether in-hospital ...


Similar News

Smartrac to Sell its RFID Inlay Business to Avery Dennison

20/11/2019 5:30PM

Smartrac Technology Group,a global leader in RFID technology and IoT solutions, today announced that it has reached a definitive agreement to sell its RFID Transponder Division to Avery Dennison Corporation. ...

Use Code ADDA52POOL and Avail Cool Offers at Adda52 Rummy

20/11/2019 5:23PM

Adda52 Rummy owned by Gaussian Networks Pvt Ltd has partnered with FC GOA for second consecutive year as Title sponsor for sixth edition of ISL 2019 held at Goa. Keeping customer satisfaction as the primary ...